Active Pharmaceutical Ingredients (API) Market Overview with Detailed Analysis, Competitive landscape Forecast to 2023
Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690
Apart from increased healthcare expenditure by the urban populations across the world and rapid increment people aged over 60 years, the global API market stands to gain addition traction from the increase in drug master file (DMF) filing from Indian companies. On the other hand, adverse regulatory policies are foreseen as a restraint that will curtail the progress of the API market. That being said, patent expiry of lucrative biological drugs is expected to open new opportunities in this market over the course of the aforementioned forecast period.
Generic API Market Anticipated to Grow Quickly in Near Future
Based on drug type, the active pharmaceutical ingredients market has been segmented into branded, generic, and over the counter (OTC). Among these, branded prescription drugs are the most profitable segment, promising to generate a revenue of US$164,481.9 million by the end of 2023. On the other hand, the generic prescription drugs segment is expected to grow at the highest rate among all counterparts in the forecast period of 2017 to 2023. With the rising cost of healthcare, governments and payers are pushing for increasing generics consumption over branded drugs, and thus driving growth of the generic APIs market. Additionally, several major pharmaceutical companies are also focusing on generic drugs along with branded drugs due to eroding product pipeline and patent expirations.
Read Report Overview: https://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html
Captive Manufacturing to Remain Prominent Segment Until 2023
API market segmentation by manufacturing process: captive and contract. In 2017, the captive manufacturing segment generated a revenue of US$100,476.0 million. And, although the demand for the same is expected to expand at a lower than the average CAGR of 6.1% during 2017 to 2023, the segment will hold onto its leading position. The captive API manufacturing market segment includes the ingredients that are produced for internal consumption of a pharmaceutical company, and is usually preferred in cases involving sensitive or patent-protected drugs. The captive or in-house API manufacturing segment, once dominated by Europe, is steadily shifting toward Asia-Pacific where low cost of manufacturing as well as demand from generic manufacturers is huge. By the end of 2023, the segment is estimated to be worth US$143,042.2 million.
Demand for Biological APIs Expanding Quicker than Synthetic Chemicals
On the basis of API type, the report bifurcates the market into synthetic chemicals and biological. While the synthetic chemical API segment is expected to remain the most profitable category, promising to generate a demand worth of US$144,838.9 million by 2023, the biological API segment is showcasing stronger growth potential. Presently, most of the biologics are manufactured in-house due to intellectual property concerns and quality issues. However, the manufacturing of biological APIs is a very complex and challenging process. Hence, innovator companies are outsourcing the segment to contract manufacturing companies who have biological production expertise.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1690
The report has also determined the potential of demand that will be forthcoming from the therapeutic areas of diseases pertaining to cardiovascular, oncology, NSAIDs, musculoskeletal, neurological, metabolic, and others. Among these, cardiovascular, neurological, and metabolic disorders have been identified as the prominent therapeutic areas, collectively providing for more than half of the total demand in the global active pharmaceutical ingredients market.
The U.S. to Sustain North America as Most Lucrative Region
Region-wise, North America is currently most profitable and is primed to remain so until 2023 too, when it will generate a demand worth of US$69,396.6 million. North America is the leading consumer of APIs; hence, API exporters consider it the most attractive market. India and China are the major suppliers of APIs to North America due to low production and labor costs. Biologics have become one of the top-selling drugs in North America in the recent past. Thus, the expected market entry of biosimilars with flexible regulatory process would boost the API market in the region. Country-wise, although the U.S. API market is showing a sluggish growth rate, it will remain more profitable than any other across the globe, having generated a revenue of US$44,940.9 million as of 2017.
BASF, Bayer, DuPont, and Dow Chemicals are some of the most prominent players currently operating in the global active pharmaceutical ingredients market.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Active Pharmaceutical Ingredients (API) Market Overview with Detailed Analysis, Competitive landscape Forecast to 2023 here
News-ID: 1111725 • Views: 159
More Releases from TMR - Research Reports
Visualization and 3D Rendering Software Market: On-Premise Deployment Presently …
The global market for visualization and 3D rendering features a largely consolidated vendor landscape, with the leading three vendors accounting for a nearly 80% of the overall revenue generated in the market in 2016, observes Transparency Market Research in a recent report. These three vendors, namely Autodesk Inc., Dassault Systems, and NVIDIA Corporation, have strengthened their positions in the market with the help of cost competitive pricing, continuous introduction of
Digital Door Lock Systems Market: Enhanced Security Requirements to Propel the D …
According to a new market report published by Transparency Market Research titled “Digital Door Lock Systems Market–Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026,” the global digital door lock systems market was valued at US$ 1,059.5 Mn in 2017 and is expected to expand at a CAGR of 30.25% from 2018 to 2026, reaching US$ 14,877.6 Mn by the end of the forecast period. digital door lock systems market
Transportation Management System Market: Advance Technologies in All the Sectors …
A transportation management system (TMS) refers to a subset of supply chain management and is centered mostly on logistics and transportation. The augmented use of cloud computing technologies for managing supply chain activities is one of the significant and major trends that have been prevailing in the world market for transportation management systems. Cloud-based deployments, in general, need less configuration and customization. These two factors are triggering down the cost
Energy Recovery Ventilators Market: Rising Awareness of Importance of Indoor Air …
Characterized by the presence of a handful of dominant players, namely United Technologies Corp., LG Electronics, Daikin Industries Ltd., Fujitsu Ltd., and Munters Corp., the global energy recovery ventilators market features intense competition, reveals Transparency Market Research (TMR) in a new report. Going forward, the rising number of players seeking entry will further intensify competition in the market. Expansion of product portfolio which has been the focus of established companies to
More Releases for API
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The
Global Biotech API Market Analysis
RNCOS has recently added a new Market Research Report titled, “Global Biotech API Market Analysis” to its report gallery. Biotech APIs contribute a very low share in the global API market with synthetic API’s accounting for majority of the formulations. However, with the revolutionary growth in the biopharmaceutical industry and gaining applications of biotech drugs, biotech API’s are sure to see a highly prospective market in the future. As per our